EPAD Scotland is a continuation of the EPAD LCS designed to idenitfy the earliest markers of Alzheimer's Disease
Title: European Prevention of Alzheimer's Disease Scotland Longitudinal Cohort Study
Short title: EPAD Scotland
Chief Investigator: Prof Craig Ritchie, University of Edinburgh
Edinburgh PI: Prof Craig Ritchie, University of Edinburgh
Ethics ref: 21/NI/0100
Funder: Alzheimer’s Disease Drug Foundation (ADDF), and Scottish Neurological Research Fund (SNRF)
Dates (estimated): April 2022 - Ongoing (subject to funding)
Synopsis: The European Prevention of Alzheimer’s Disease (EPAD) longitudinal cohort study (LCS) ended in 2020. EPAD was a large European wide collaboration aimed at understanding dementia and forming clinical trials of new medicines to fight against Alzheimer’s disease. EPAD generated a rich pool of cognitive, neuroimaging, clinical and biomarker data, which is to be used to identify early risk factors for Alzheimer’s disease. Now, follow-on studies to EPAD are being set up locally within each host country in order to continue collecting longitudinal data from previous EPAD participants and from new participants. This new data will complement the existing data by building longitudinal models of change in early Alzheimer’s disease.
Aims: To find the earliest cognitive and biological markers of Alzheimer’s disease
Recruiting: Yes. People without dementia who were previously enrolled on EPAD LCS are eligible to take part. People previously enrolled on the CHARIOT PRO study are also invited to take part. EPAD Scotland would additionally like to invite anyone aged over 50 who does not have a university degree to prticipate. To find out more or register your interest please contact us or call 0131 651 7657.
The video below was featured on the EPAD LCS Youtube channel and describes Amyloid and the risk for Alzheimer's Disease, as well as how study participants may be invited to take part in clincial trials on Amyloid in the future.
- Video: EPAD and Amyloid
- This animation movie tries to explain what we currently understand about amyloid and how it relates to dementia. EPAD Research Participants may be invited to take part in a clinical trial if test results suggest abnormal levels of a protein called amyloid. If abnormal levels are present, it may mean that person has a higher risk of developing Alzheimer's dementia in later life.